Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 EUR | -1.42% | +15.83% | +60.14% |
2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 22.53 | 8.675 |
Enterprise Value (EV) 1 | 20.92 | 9.751 |
P/E ratio | -8.52 x | -3.16 x |
Yield | - | - |
Capitalization / Revenue | 235 x | 44 x |
EV / Revenue | 219 x | 49.4 x |
EV / EBITDA | -6.84 x | -3.1 x |
EV / FCF | - | - |
FCF Yield | - | - |
Price to Book | 13.7 x | -8.2 x |
Nbr of stocks (in thousands) | 4,365 | 4,390 |
Reference price 2 | 5.160 | 1.976 |
Announcement Date | 22-04-21 | 23-04-25 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net sales 1 | 0.2085 | 0.0957 | 0.1973 |
EBITDA 1 | -0.895 | -3.06 | -3.142 |
EBIT 1 | -0.9879 | -3.215 | -3.244 |
Operating Margin | -473.81% | -3,358.25% | -1,644% |
Earnings before Tax (EBT) 1 | -0.9905 | -3.21 | -3.229 |
Net income 1 | -0.7911 | -2.647 | -2.749 |
Net margin | -379.43% | -2,764.69% | -1,393.3% |
EPS 2 | -0.2420 | -0.6059 | -0.6261 |
Free Cash Flow | - | - | - |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 22-04-21 | 22-04-21 | 23-04-25 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net Debt 1 | 1.22 | - | 1.08 |
Net Cash position 1 | - | 1.61 | - |
Leverage (Debt/EBITDA) | -1.364 x | - | -0.3424 x |
Free Cash Flow | - | - | - |
ROE (net income / shareholders' equity) | - | 1,212% | -935% |
ROA (Net income/ Total Assets) | - | -77.8% | -65% |
Assets 1 | - | 3.401 | 4.232 |
Book Value Per Share 2 | -0.6400 | 0.3800 | -0.2400 |
Cash Flow per Share 2 | 0.0200 | 0.0400 | 0.0600 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 22-04-21 | 22-04-21 | 23-04-25 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+60.14% | 6.63M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALMDP Stock
- Financials Medesis Pharma S.A.